Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored vs Empiric Therapy for H. pylori Eradication
NCT04107194Phase 3Unknown
- Sponsor
- University of Bari Aldo Moro
- Start
- Jan 2020
- Primary completion
- Feb 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amoxicillin, clarithromycin, metronidazole, tetracycline, bismuth subcitrate and 2 more in Helicobacter pylori infection (2 arms), sponsored by University of Bari Aldo Moro. Primary endpoint: Eradication rate at 30 days. Status: unknown.
02
Drugs
amoxicillinclarithromycinmetronidazoletetracyclinebismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT04107194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04107194.